Lantern Pharma Q2 FY26 earnings call LTRN

Lantern Pharma formally established Open Medicine AI (OMAI) as a separate company in August 2026, complete with commercial licenses and agreements. This strategic move aims to leverage OMAI's multi-agentic AI co-scientists in a commercial setting, moving beyond single-model AI approaches. The company believes this orchestrated system, which integrates specialized agents for various drug discovery tasks, will become the standard infrastructure for multidisciplinary drug discovery, offering transparency and audit trails. The separation is driven by the differing valuation metrics for clinical drug development and enterprise software, allowing OMAI to raise its own capital and pursue its commercial model independently, while Lantern retains 100% ownership initially and full access to the platform for its own drug development.

The Phase II HARMONIC trial for LP-300 in never-smokers with non-small cell lung cancer (NSCLC) showed promising emerging data, particularly in L858R patients. Among those completing 6 cycles, median progression-free survival (PFS) reached 8.9 months, with a 77% clinical benefit rate and over 70% target lesion reduction. The trial protocol has been amended to concentrate enrollment on L858R patients, extend treatment from 6 to 8 cycles, and adopt a single-arm design for increased efficiency and reduced cost. Enrollment is expected to resume in the U.S. and Taiwan, targeting 15-16 additional patients over the next 4-6 months.

LP-184 achieved several significant milestones, including EMA clearance in July 2026 for an investigator-initiated Phase Ib/II trial in advanced bladder cancer at Rigshospitalet in Copenhagen. This 39-patient trial will focus on a dual biomarker strategy. The FDA also cleared a Phase Ib/II trial for LP-184 monotherapy in relapsed or refractory triple-negative breast cancer, which will enroll up to 40 patients across two dose cohorts. Furthermore, Lantern received a notice of allowance in July for a patent covering a 3-gene selection method (PTGR1, PTPN14, ASPH) to identify patients most likely to respond to LP-184 in ovarian, liver, kidney, and thyroid cancers.

LP-284 continues its development in hematologic malignancies and adult soft tissue sarcomas, having secured orphan designation earlier in the year. The Starlight program (STAR-001), which utilizes LP-184 for brain cancers, has demonstrated strong preclinical data by targeting ERCC3 protein degradation using spironolactone. Starlight is 100% owned by Lantern, holds its own INDs and regulatory designations, and is being advanced for rare pediatric brain tumors such as ATRT, hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors. Each of these indications is independently eligible for a priority review voucher, valued at $150 million to $200 million or more, with Lantern holding four such potential vouchers.

Lantern Pharma reported a 25% reduction in total operating expenses year-over-year, reflecting highly disciplined execution despite advancing multiple clinical programs and launching OMAI. The company emphasizes its efficient operating model, which enables the progression of programs from AI-derived insights to first-in-human clinical trials in under three years and at a cost of approximately $2 million to $3 million per program, significantly below the industry norm of 5-10 years and $25 million to $100 million. This efficiency, coupled with three molecules in clinical trials and over 100 patients dosed, underpins Lantern's core advantage.

The remainder of 2026 is considered a defining year for Lantern Pharma, with a planned launch in 2027. The company views its business model, which integrates a clinically validated platform with three drugs in trials and a commercially accessible AI platform, as a powerful complement. The AI tools and services are projected to grow into several hundred million dollars in stand-alone value within the larger $10 billion market for AI in drug discovery. Lantern is exploring ways to distribute OMAI shares to its shareholders, allowing them to benefit from its monetization through private financings and a potential public listing.